ESSA Pharma (EPIX) Shares Down 10.7%

Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) dropped 10.7% during trading on Wednesday . The company traded as low as $0.24 and last traded at $0.25. Approximately 764,200 shares were traded during trading, an increase of 694% from the average daily volume of 96,195 shares. The stock had previously closed at $0.28.

Several research analysts have issued reports on the company. Dawson James restated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research report on Monday, September 11th. Finally, Bloom Burton cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. ESSA Pharma presently has an average rating of “Hold” and an average price target of $4.75.

The company has a debt-to-equity ratio of -3.00, a current ratio of 2.32 and a quick ratio of 2.32.

COPYRIGHT VIOLATION NOTICE: “ESSA Pharma (EPIX) Shares Down 10.7%” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

What are top analysts saying about ESSA Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ESSA Pharma Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit